# EDGAR Filing Document

**Accession Number:** 0001395937
**File Stem:** 0001193125-26-076822
**Filing Date:** 2026-2
**Character Count:** 20560
**Document Hash:** 2d55c58b6dbde8300c35306a7d852ee4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-076822.hdr.sgml**: 20260226

**ACCESSION NUMBER**: 0001193125-26-076822

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20260226

**DATE AS OF CHANGE**: 20260226

**EFFECTIVENESS DATE**: 20260226

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Syndax Pharmaceuticals Inc
- **CENTRAL INDEX KEY:** 0001395937
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 320162505
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293792
- **FILM NUMBER:** 26689041

**BUSINESS ADDRESS:**
- **STREET 1:** 730 THIRD AVENUE
- **STREET 2:** 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 781-419-1400

**MAIL ADDRESS:**
- **STREET 1:** 730 THIRD AVENUE
- **STREET 2:** 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**As filed with the Securities and Exchange Commission on February 26, 2026**

**Registration No. 333-** 

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

_______________________________

**Form S-8**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

_______________________________

**Syndax Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

_______________________________

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;**32-0162505** |
| &nbsp;&nbsp;(State or other jurisdiction of incorporation or organization) | &nbsp;&nbsp;(IRS employer identification number) |

---

**730 Third Avenue**

**9th Floor**

**New York, New York 10017**

**(781) 419-1400**

(Address of principal executive offices)

_______________________________

**2015 Omnibus Incentive Plan**

**2015 Employee Stock Purchase Plan**

(Full titles of the plans)

_______________________________

**Michael A. Metzger**

**Chief Executive Officer**

**Syndax Pharmaceuticals, Inc.**

**730 Third Avenue**

**9th Floor**

**New York, New York 10017**

**(781) 419-1400**

(Name, address and telephone number of agent for service)

---

| | |
|:---|:---|
| **Laura A. Berezin**<br>**Jaime L. Chase**<br>**Cooley LLP**<br>**1700 Seventh Avenue, Suite 1900**<br>**Seattle, Washington 98101**<br>**(206) 452-8700** | **Luke J. Albrecht**<br>**General Counsel & Secretary**<br>**Syndax Pharmaceuticals, Inc.**<br>**730 Third Avenue**<br>**9th Floor**<br>**New York, New York 10017**<br>**(781) 419-1400** |

---

_______________________________

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| &nbsp;&nbsp;Large accelerated filer  | &nbsp;&nbsp;Accelerated filer  |
| &nbsp;&nbsp;Non-accelerated filer  | &nbsp;&nbsp;Smaller reporting company  |
| &nbsp;&nbsp;Emerging growth company  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 

------

**Explanatory Note** 

This Registration Statement on Form S-8 ("***Registration Statement***") is being filed for the purpose of registering 3,746,239 shares of the Registrant's common stock, par value $0.0001 per share (the "***Common Stock***"), comprising (i) 3,496,239 additional shares of the Registrant's common stock under the Registrant's 2015 Omnibus Incentive Plan (the "***2015 Plan***") pursuant to the provisions of the 2015 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2015 Plan on January 1, 2026, and (ii) 250,000 additional shares of the Registrant's Common Stock under the Registrant's 2015 Employee Stock Purchase Plan (the "***ESPP***") pursuant to the provisions of the ESPP providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the ESPP on January 1, 2026.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by References** 

The Registrant previously registered shares of its Common Stock for issuance under the 2015 Plan and the ESPP under Registration Statements on Form S-8 filed with the Securities and Exchange Commission on [<u>March 25, 2016</u>](https://www.sec.gov/Archives/edgar/data/1395937/000119312516518181/d166957ds8.htm) (File No. 333-210412), [<u>August 25, 2017</u>](https://www.sec.gov/Archives/edgar/data/1395937/000119312517268644/d430439ds8.htm) (File No. 333-220172), [<u>August 8, 2018</u>](https://www.sec.gov/Archives/edgar/data/1395937/000156459018020504/sndx-s8.htm) (File No. 333-226678), [<u>August 7, 2019</u>](https://www.sec.gov/Archives/edgar/data/1395937/000156459019030084/sndx-s8.htm) (File No. 333-233083), [<u>August 6, 2020</u>](https://www.sec.gov/Archives/edgar/data/1395937/000156459020037767/sndx-s8.htm) (File No. 333-241654), [<u>August 9, 2021</u>](https://www.sec.gov/Archives/edgar/data/1395937/000156459021042630/sndx-s8.htm) (File No. 333-258628), [<u>March 1, 2022</u>](https://www.sec.gov/Archives/edgar/data/1395937/000156459022008120/sndx-s8.htm) (File No. 333-263185), [<u>February 28, 2023</u>](https://www.sec.gov/Archives/edgar/data/1395937/000095017023005102/sndx-20223-02-s8.htm) (File No. 333-270093), [<u>February 27, 2024</u>](https://www.sec.gov/Archives/edgar/data/1395937/000119312524048118/d769709ds8.htm) (File No. 333-277423) and [<u>March 4, 2025</u>](https://www.sec.gov/Archives/edgar/data/1395937/000095017025031354/sndx-20250304.htm) (File No. 333-285529). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

**Item 8. Exhibits**

The exhibits to this Registration Statement are listed below and incorporated by reference herein.

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Exhibit<br>Number** | &nbsp;&nbsp;**Exhibit Description** |
| &nbsp;&nbsp;4.1 | &nbsp;&nbsp;[<u>Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, SEC (File No. 001-37708), filed with the SEC on March 8, 2016).</u>](https://www.sec.gov/Archives/edgar/data/0001395937/000119312516496764/d119516dex31.htm) |
| &nbsp;&nbsp;4.2 | &nbsp;&nbsp;[<u>Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K (File No. 001-37708), as filed with the SEC on May 18, 2023).</u>](https://www.sec.gov/Archives/edgar/data/1395937/000095017023022802/sndx-ex3_1.htm) |
| &nbsp;&nbsp;4.3 | &nbsp;&nbsp;[<u>Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K, SEC (File No. 001-37708), filed with the SEC on December 19, 2025).</u>](https://www.sec.gov/Archives/edgar/data/1395937/000119312525326961/sndx-ex3_1.htm) |
| &nbsp;&nbsp;5.1 | &nbsp;&nbsp;[<u>Opinion of Cooley LLP.</u>](sndx-ex5_1.htm) |
| &nbsp;&nbsp;23.1 | &nbsp;&nbsp;[<u>Consent of Independent Registered Accounting Firm.</u>](sndx-ex23_1.htm) |
| &nbsp;&nbsp;23.2 | &nbsp;&nbsp;[<u>Consent of Cooley LLP (included in Exhibit 5.1).</u>](sndx-ex5_1.htm) |
| &nbsp;&nbsp;24.1 | &nbsp;&nbsp;[<u>Power of Attorney (included on the signature page to this Registration Statement).</u>](#poa) |
| &nbsp;&nbsp;99.1 | &nbsp;&nbsp;[<u>2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 4.13 to the Company's Registration Statement on Form S-8, SEC (File No. 333-210412), as filed with the SEC on March 25, 2016).</u>](https://www.sec.gov/Archives/edgar/data/0001395937/000119312516518181/d166957dex413.htm) |
| &nbsp;&nbsp;99.2 | &nbsp;&nbsp;[<u>2015 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 4.16 to the Company's Registration Statement on Form S-8, SEC (File No. 333-210412), as filed with the SEC on March 25, 2016).</u>](https://www.sec.gov/Archives/edgar/data/0001395937/000119312516518181/d166957dex416.htm) |
| &nbsp;&nbsp;107 | &nbsp;&nbsp;[<u>Calculation of Filing Fee Table.</u>](sndx_exfilingfees.htm) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of New York, State of New York, on February 26, 2026.

**Syndax Pharmaceuticals, Inc.**

By: <u>/s/ Michael A. Metzger</u>

Michael A. Metzger<br>Chief Executive Officer

**POWER OF ATTORNEY**

**KNOW ALL PERSONS BY THESE PRESENTS**, that each person whose signature appears below constitutes and appoints Michael A. Metzger and Luke J. Albrecht, and each of them, his true and lawful attorney-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Signature** | &nbsp;&nbsp;**Title** | &nbsp;&nbsp;**Date** |
| &nbsp;&nbsp;/s/ Michael A. Metzger | &nbsp;&nbsp;Chief Executive Officer and Director<br>(Principal Executive Officer) | &nbsp;&nbsp;February 26, 2026 |
| &nbsp;&nbsp;Michael A. Metzger |  |  |
| &nbsp;&nbsp;/s/ Keith A. Goldan | &nbsp;&nbsp;Chief Financial Officer<br>(Principal Financial Officer) | &nbsp;&nbsp;February 26, 2026 |
| &nbsp;&nbsp;Keith A. Goldan |  |  |
| &nbsp;&nbsp;/s/ Dennis G. Podlesak | &nbsp;&nbsp;Chairman of the Board of Directors | &nbsp;&nbsp;February 26, 2026 |
| &nbsp;&nbsp;Dennis G. Podlesak |  |  |
| &nbsp;&nbsp;/s/ Martin H. Huber, M.D. | &nbsp;&nbsp;Director | &nbsp;&nbsp;February 26, 2026 |
| &nbsp;&nbsp;Martin H. Huber, M.D. |  |  |
| &nbsp;&nbsp;/s/ Jennifer Jarrett | &nbsp;&nbsp;Director | &nbsp;&nbsp;February 26, 2026 |
| &nbsp;&nbsp;Jennifer Jarrett |  |  |
| &nbsp;&nbsp;/s/ Keith A. Katkin  | &nbsp;&nbsp;Director | &nbsp;&nbsp;February 26, 2026 |
| &nbsp;&nbsp;Keith A. Katkin |  |  |
| &nbsp;&nbsp;/s/ Pierre Legault | &nbsp;&nbsp;Director | &nbsp;&nbsp;February 26, 2026 |
| &nbsp;&nbsp;Pierre Legault |  |  |
| &nbsp;&nbsp;/s/ Aleksandra Rizo, M.D., Ph.D. | &nbsp;&nbsp;Director | &nbsp;&nbsp;February 26, 2026 |

---

------

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Signature** | &nbsp;&nbsp;**Title** | &nbsp;&nbsp;**Date** |
| &nbsp;&nbsp;Aleksandra Rizo, M.D., Ph.D. |  |  |

---

------

## Exhibit 5.1

**Exhibit 5.1**

![img160177385_0.gif](img160177385_0.gif)

February 26, 2026

**Syndax Pharmaceuticals, Inc.**

730 Third Avenue

9th Floor

New York, New York 10017

Ladies and Gentlemen:

We have acted as counsel to Syndax Pharmaceuticals, Inc., a Delaware corporation (the "***Company***"), in connection with the filing by the Company of a registration statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") covering the offering of up to 3,746,239 shares (the "***Shares***") of the Company's common stock, par value $0.0001 per share ("***Common Stock***"), consisting of (i) 3,496,239 shares of Common Stock issuable pursuant to the Company's 2015 Omnibus Incentive Plan (the "***2015 Plan***") and (ii) 250,000 shares of Common Stock issuable pursuant to the Company's 2015 Employee Stock Purchase Plan (the "***ESPP***", together with the 2015 Plan, the "***Plans***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and the related prospectuses, (b) the Company's certificate of incorporation and bylaws, each as currently in effect, (c) the Plans, and (d) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures; the authenticity of all documents submitted to us as originals; the conformity to originals of all documents submitted to us as copies; the accuracy, completeness and authenticity of certificates of public officials; and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and the related prospectuses, will be validly issued, fully paid, and nonassessable (except as to shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

This opinion is limited to the matters expressly set forth in this letter, and no opinion should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

------

![img160177385_1.gif](img160177385_1.gif)

Syndax Pharmaceuticals, Inc.

February 26, 2026

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

Sincerely,

Cooley LLP

By: <u>/s/ Jaime L. Chase</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jaime L. Chase

Cooley LLP 1299 Pennsylvania Avenue, NW Washington, DC 20004-2400<br>t: (202) 842 7800 f: (202) 842 7899 cooley.com

------

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our reports dated February 26, 2026, relating to the financial statements of Syndax Pharmaceuticals, Inc. and subsidiaries and the effectiveness of Syndax Pharmaceuticals, Inc. and subsidiaries' internal control over financial reporting, appearing in the Annual Report on Form 10-K of Syndax Pharmaceuticals, Inc. for the year ended December 31, 2025.

/s/ Deloitte & Touche LLP

Boston, Massachusetts

February 26, 2026

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

**Exhibit 107**

**Calculation of** Filing Fee **Tables**

**Form** S-8

(Form Type)

Syndax Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;Security Type | &nbsp;&nbsp;**Security Class Title** | &nbsp;&nbsp;**Fee Calculation Rule** | &nbsp;&nbsp;**Amount Registered**  | &nbsp;&nbsp;**Proposed Maximum Offering Price Per Unit** | &nbsp;&nbsp;**Maximum Aggregate Offering Price** | &nbsp;&nbsp;**Fee Rate** | &nbsp;&nbsp;**Amount of Registration Fee** |
| &nbsp;&nbsp;Equity (1) | &nbsp;&nbsp;**2015 Omnibus Incentive Plan** (Common Stock, $0.0001 par value per share) | &nbsp;&nbsp;Rule 457(c) and 457(h) | &nbsp;&nbsp;3496239  | &nbsp;&nbsp;$19.93 | &nbsp;&nbsp;$69680043.27 | &nbsp;&nbsp;$138.10 per $1,000,000 | &nbsp;&nbsp;$9622.81 |
| &nbsp;&nbsp;Equity (2) | &nbsp;&nbsp;2015 Employee Stock Purchase Plan<br>(Common Stock, $0.0001 par value per share)<br>| &nbsp;&nbsp;Rule 457(c) and 457(h) | &nbsp;&nbsp;250000  | &nbsp;&nbsp;$16.95 | &nbsp;&nbsp;$4237500.00 | &nbsp;&nbsp;$138.10 per $1,000,000 | &nbsp;&nbsp;$585.20 |
| &nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;**Total Offering Amounts** |  | &nbsp;&nbsp;**$73917543.27** |  | &nbsp;&nbsp;**$10208.01** |
| &nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;**Total Fee Offsets** |  |  |  | &nbsp;&nbsp;**—** |
| &nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;**Net Fee Due** |  |  |  | &nbsp;&nbsp;**$10208.01** |

---

(1)In addition to the number of shares of the common stock of Syndax Pharmaceuticals, Inc. (the "***Registrant***") stated above, pursuant to Rule 416 under the Securities Act of 1933, as amended (the "***Securities Act***"), this Registration Statement on Form S-8 ("***Registration Statement***") shall also cover an indeterminate number of shares of common stock that may become issuable under the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of outstanding shares of common stock of the Registrant. The "Proposed Maximum Offering Price Per Unit" and "Maximum Aggregate Offering Price" are estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and (h) of the Securities Act based on a per share price of $19.93, the average of the high ($20.40) and low ($19.45) price of the common stock on February 23, 2026 as reported on The Nasdaq Global Select Market.

(2)In addition to the number of shares of the common stock of the Registrant stated above, pursuant to Rule 416 under the Securities Act, this Registration Statement shall also cover an indeterminate number of shares of common stock that may become issuable under the Syndax Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan (the "***ESPP***") by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of outstanding shares of common stock of the Registrant. The "Proposed Maximum Offering Price Per Unit" and "Maximum Aggregate Offering Price" are estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and (h) of the Securities Act based on a per share price of $16.95, the average of the high ($20.40) and low ($19.45) price of the common stock on February 23, 2026, as reported on The Nasdaq Global Select Market, multiplied by 85%, which is the percentage of the trading price per share applicable to purchasers under the ESPP.

------